| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 10801 | 2021 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 185 | 2022 |
| Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally … A Sánchez-Muñoz, AM García-Tapiador, E Martínez-Ortega, ... Clinical and Translational Oncology 10, 646-653, 2008 | 74 | 2008 |
| Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study) M Provencio, E Carcereny, D Rodríguez-Abreu, R López-Castro, ... Translational lung cancer research 8 (4), 461, 2019 | 62 | 2019 |
| A randomized open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: the European Thoracic Oncology Platform (ETOP … S Peters, S Danson, B Hasan, U Dafni, N Reinmuth, M Majem, ... Journal of Thoracic Oncology 15 (10), 1647-1656, 2020 | 38 | 2020 |
| Lung cancer symptoms at diagnosis: results of a nationwide registry study A Ruano-Ravina, M Provencio, VC de Juan, E Carcereny, T Moran, ... ESMO open 5 (6), e001021, 2020 | 32 | 2020 |
| Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry F Franco, E Carcereny, M Guirado, AL Ortega, R López-Castro, ... PLoS One 16 (6), e0251761, 2021 | 30 | 2021 |
| Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine … M Provencio, R Serna-Blasco, F Franco, V Calvo, A Royuela, M Auglytė, ... European Journal of Cancer 149, 61-72, 2021 | 28 | 2021 |
| A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice M Merino Almazán, JM Duarte Pérez, JF Marín Pozo, ... International Journal of Clinical Pharmacy 41, 272-279, 2019 | 28 | 2019 |
| SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020) E Nadal, J Bosch-Barrera, S Cedrés, J Coves, R García-Campelo, ... Clinical and Translational Oncology 23, 980-987, 2021 | 24 | 2021 |
| Human plasma metabolomics for biomarker discovery: Targeting the molecular subtypes in breast cancer L Díaz-Beltrán, C González-Olmedo, N Luque-Caro, C Díaz, ... Cancers 13 (1), 147, 2021 | 24 | 2021 |
| Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally … M Provencio, M Majem, M Guirado, B Massuti, R de Las Peñas, AL Ortega, ... Lung Cancer 153, 25-34, 2021 | 22 | 2021 |
| Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL) R Garcia-Campelo, O Arrieta, B Massuti, D Rodriguez-Abreu, ... Lung Cancer 150, 62-69, 2020 | 22 | 2020 |
| Are there differences by sex in lung cancer characteristics at diagnosis?—a nationwide study A Ruano-Ravina, M Provencio, VC de Juan, E Carcereny, A Estival, ... Translational Lung Cancer Research 10 (10), 3902, 2021 | 20 | 2021 |
| Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial A Romero, E Jantus‐Lewintre, B García‐Peláez, A Royuela, A Insa, ... Molecular Oncology 15 (1), 43-56, 2021 | 20 | 2021 |
| A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage … E Felip, P Brunsvig, N Vinolas, S Ponce Aix, E Carcereny Costa, ... Journal of Clinical Oncology 37 (15_suppl), 9098-9098, 2019 | 20 | 2019 |
| Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide … A Sánchez-Muñoz, R Duenas-Garcia, A Jaen-Morago, E Carrasco, ... American journal of clinical oncology 33 (5), 432-437, 2010 | 19 | 2010 |
| Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer with high tumor mutation burden: a nonrandomized … M Provencio, AL Ortega, J Coves-Sarto, V Calvo, R Marsé-Fabregat, ... JAMA oncology 9 (3), 344-353, 2023 | 18 | 2023 |
| Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation M Barquín, V Calvo, F García-García, B Nuñez, E Sánchez-Herrero, ... Cancer Epidemiology 67, 101737, 2020 | 18 | 2020 |
| Oncoguía: Cáncer Cervicouterino G Montalvo, J Coronel, A Alvarado, D Cantú, D Flores, A Ortega, ... Cancerología 6, 61-69, 2011 | 15 | 2011 |
Manuel DomineAssociate Head Oncology. Fundación Jiménez Díaz. IIS - FJD. Head Thoracic Oncology & Clinical TrialsVerified email at fjd.es
